Skip to main content

Eva Polverino

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca

Eva Polverino

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca

Projects

VALUE-Dx- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

IP: Eva Polverino
Collaborators: Monica Kruger
Funding agency: The Innovative Medicines Initiative
Funding: 30000
Reference: VALUE-DX_IMI2-2017
Duration: 01/04/2019 - 30/09/2024

Grup de Recerca de Pneumologia

IP: Jaume Ferrer Sancho
Collaborators: Esther Rodríguez González, Sergi Martí Beltran, Mª Jose Jurado Luque, Marc Miravitlles Fernández, Ana Villar Gomez, Antonio Román Broto, Antonio Álvarez Fernandez, Victor Monforte Torres, Grup de Recerca de Pneumologia, Grup de Recerca de Pneumologia, Odile Romero Santo-Tomas, Sonia Lopez Rodriguez, Montserrat Murillo Andres, Miriam Barrecheguren Fernández, Carles Bravo Masgoret, Mario Culebras Amigo, Fco. Javier Muñoz Gall, Marta Castro D la Visitación, Gabriel Sampol Rubio, Maria Antonia Ramon Belmonte, Rosa Lloria Verges, Mercedes Pallero Castillo, Mª Jesús Cruz Carmona, Cristina Berastegui Garcia, Manuel López Meseguer, Susana Gómez Olles, Berta Saez Gimenez, Iñigo Ojanguren Arranz, Eva Polverino
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2017SGR0434
Duration: 01/01/2017 - 30/09/2021

_Bronquiectasias no asociadas a fibrosis quística del adulto: biomarcadores y factores pronósticos.

IP: Eva Polverino
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: VHIR/PREDOC/2017/MIRANDA
Duration: 10/05/2018 - 08/05/2019

iABC: Inhaled antibiotics in bronchiectasis and cystic fibrosis

IP: Eva Polverino
Collaborators: Sonia Lopez Rodriguez
Funding agency: The Innovative Medicines Initiative
Funding: 121599
Reference: IABC_IMI2-2015
Duration: 01/01/2017 - 30/06/2023

Related news

Dr. Miravitlles’ career was recognized during the 57th edition of the SEPAR National Congress held in Valencia.

Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Related professionals

Fernando Clau Terre

Fernando Clau Terre

Read more
Lydia Dux-Santoy Hurtado

Lydia Dux-Santoy Hurtado

Main researcher
Cardiovascular Diseases
Read more
Noelia Díaz Troyano

Noelia Díaz Troyano

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Asunción Fernández Rodríguez

Asunción Fernández Rodríguez

Research technician
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.